2 5 ABC ® Enabled Mainstay Biologics Target Product Profiles What are the potential implications and upsides for Zenkuda and KSI-501 in the Phase 3 DAYBREAK in wAMD, if successful? Well-tolerated safety profile Non-inferior vision gains vs. aflibercept Q8W Strong and immediate disease control Potential to close the ‘immediacy’ gap Flexible long-interval dosing 1-month through 6-month Not assessed Better vision gains vs anti-VEGF monotherapy (aflibercept Q8W) Not assessed Path to wAMD approval ZENKUDA KSI-501 Demonstrate immediate disease control and 4/5/6-month durability Explore efficacy benefit of dual IL-6 / VEGF inhibition Baseline Zenkuda differentiation KSI-501 differentiation If successful, DAYBREAK could support the following clinical and regulatory outcomes DAYBREAK objective in wAMD